About
BIO
Ended--
Last price (USDT)
1.79M
24h total (USDT)
5.76M
Total vol (USDT)
2024-12-25 09:00:00 ~ 2025-01-03 09:30:00
Trading time (UTC+0)
2025-01-03 11:00:00 ~ 2025-01-03 15:00:00
Delivery time (UTC+0)
Total supply3.32B
Resources
Introduction
BIO is an open network for biotech acceleration that directs funding to the best early-stage science. With BIO, patients, scientists and biotech builders can collectively fund, build & own portfolios of tokenized biotech projects. BIO protocol provides funding, incentives & liquidity to catalyze an on-chain scientific economy.
KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model
KALA BIO, Inc. (NASDAQ: KALA) shares rose Wednesday after the biotechnology company unveiled a strategic initiative to build an on-premises artificial intelligence infrastructure platform for the biotech sector. The company also entered a platform development and exclusive license agreement with 2624465 Ontario Inc., operating as Younet AI, for its proprietary AI research platform, Researgency. The deal grants KALA exclusive worldwide rights to deploy the platform in biotechnology during an initial 12-month term, with options to renew. Researgency Platform And Licensing Model Researgency runs entirely within a client's own infrastructure, allowing biotech and pharmaceutical companies to analyze proprietary biological data using AI without transferring sensitive datasets to external cloud platforms. KALA said most AI drug discovery platforms rely on centralized cloud models that require companies to upload proprietary data to third-party environments—an approach that can deter biotech firms seeking to protect biological datasets, trade secrets and regulatory-sensitive information. AI-driven drug discovery is expanding within a pharmaceutical R&D market exceeding $167 billion, but adoption remains limited, particularly among smaller biotech firms lacking secure AI infrastructure. KALA plans to first deploy Researgency internally using its MSC-S platform datasets and KPI-012 clinical program. Following validation, the company intends to license the platform to biotech and pharmaceutical companies through a recurring subscription model. Chief Executive Officer Avi Minkowitz said the strategy is designed to bring institutional-grade AI capabilities directly to biotech companies while allowing them to retain full control of their intellectual property. Technical Analysis The stock is currently trading 2.5% above its 20-day simple moving average (SMA) and is 3.1% below its 100-day SMA, indicating some short-term strength but potential resistance in the longer term. Over the past 12 months, shares have decreased significantly, reflecting challenges faced by the company, and are currently positioned closer to their 52-week lows than highs. The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating some bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment. Key Resistance: 50 cents Key Support: 35 cents KALA Price Action: Kala Bio shares were up 5.51% at $0.37 at the time of publication on Wednesday. Photo by PeopleImages.com – Yuri A via Shutterstock
Are healthcare stocks underperforming Biodesix (BDSX) so far this year?
Biodesix, Inc.: Outperforming in the Medical Sector While the Medical sector offers a wide array of promising stocks, it's important for investors to identify those that are excelling compared to their industry peers. Biodesix, Inc. (BDSX) stands out as a potential leader, especially when examining its performance so far this year against the broader Medical sector. Among the 928 companies that make up the Medical sector, Biodesix, Inc. is notable. The sector itself currently holds the #9 spot in the Zacks Sector Rank, which evaluates 16 sectors based on the average Zacks Rank of their constituent stocks to determine overall strength. The Zacks Rank system, which focuses on earnings projections and their revisions, is a trusted method for identifying stocks with the potential to outperform the market in the short term. At present, Biodesix, Inc. has achieved a Zacks Rank of #2 (Buy). Over the last quarter, analysts have raised their full-year earnings estimates for BDSX by 3.5%, indicating growing optimism and an improving earnings outlook for the company. Year-to-date, Biodesix, Inc. has surged approximately 131.6%, far outpacing the average 1.9% return posted by other Medical sector stocks. This impressive growth highlights BDSX’s strong performance within its sector. Other Noteworthy Performers Cabaletta Bio, Inc. (CABA) is another Medical stock that has delivered notable returns this year, climbing 50.7% since the start of the year. Analyst expectations for Cabaletta Bio, Inc.'s earnings per share have also improved, rising 1.6% over the last three months. The company currently shares the same Zacks Rank of #2 (Buy) as Biodesix. Industry Breakdown Biodesix, Inc. operates within the Medical Services industry, which comprises 66 companies and is currently ranked #90 by Zacks. On average, stocks in this group have declined by 2.5% this year, making BDSX’s positive returns even more remarkable. Meanwhile, Cabaletta Bio, Inc. is part of the Medical - Biomedical and Genetics industry, which includes 447 companies and is ranked #137. This industry has seen an average gain of 8.7% since the beginning of the year. Looking Ahead Investors interested in the Medical sector should keep a close watch on both Biodesix, Inc. and Cabaletta Bio, Inc., as their strong momentum may continue in the coming months.
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients
Year-End Cash Position, License Renewal Activity and Receivables Collections Provide Sound Financial Position to Support Growth HOLMDEL, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in biometric-centric Identity and Access Management (IAM) solutions, today announced it has secured a $1.04M license renewal and expansion order for its biometric identification solution from a foreign retail bank, a customer since 2015. Reflecting the customer’s ongoing expansion of the solution’s deployment, the value of the one-year renewal increased 30% over the prior year. BIO-key also disclosed that based on its year-end cash position of $2.7M, anticipated license renewal activity including today’s announcement, and anticipated receivables collections, it believes it has sufficient cash and anticipated cash inflows to support its growth plans internally. Michael DePasquale, BIO-key’s Chairman and CEO, commented, “We are extremely encouraged by our growing traction in larger scale deployments which we expect to bolster our financial results and working capital position moving forward. We entered 2026 on a solid financial footing with approximately $2.7M in cash and improving visibility on both renewal activity and business development opportunities. These factors, combined with our spending discipline, provide a sound working capital outlook to internally fund our growth initiatives. The bank’s biometric identification technology deployment has grown from an initial BIO-key rollout of 7M enrolled clients in 2015 to over 30M today. With ten fingerprints enrolled per client, the program now manages more than 300M fingerprints to support fast, consistent bank client identification and verification for in-branch interactions at teller stations, assisted kiosks and ATMs/automated service points. The renewal incorporates anticipated growth of 5% in client enrollment over the coming year. In addition, approximately 10,000 bank employees use BIO-key’s fingerprint technology to authenticate themselves during daily branch operations and transaction processing, helping the bank enforce strong controls and reduce the risk of unauthorized activity The system is designed to help extend the trust established during client onboarding into everyday banking. As part of the bank’s know-your-customer (KYC) processes, client fingerprints are verified against the national identity verification system. The certainty of that client identity proofing event is then tied to their BIO-key enrollment and used for positive client identification in subsequent interactions. This helps banks maintain a durable chain of trust that strengthens protection against impersonation, account takeover and fraud. “Identity assurance is becoming the control point for modern banking. As client service and operations become more automated and AI-assisted, it is essential for banks to deploy robust systems to authenticate customer interactions which can be audited. We are proud to support a ‘biometric chain of identity trust’ that helps connect day-to-day interactions, whether automated or in person, back to the bank’s original identity proofing,” said Jim Sullivan, BIO-key’s SVP of Strategy and Chief Legal Officer. “BIO-key is proud to provide a scalable biometric platform that has supported this customer’s extraordinary growth over the last decade.” About BIO-key International, Inc. BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless and passwordless biometric FIDO Passkey and in-person authentication options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in March: Leerink Partners Global Healthcare Conference Date: March 9, 2026 Time: 3:00 p.m. ET Format: Fireside Chat Location: Miami Beach, FL Barclays 28 th Annual Global Healthcare Conference Date: March 11, 2026 Time: 8:30 a.m. ET Format: Fireside Chat Location: Miami Beach, FL About SAB BIO SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. CONTACTS Investors: Cristi Barnett Media: Sheila Carlson
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS (“Inzymes”), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion of final development activities under the companies’ collaboration agreement. Completion of these development activities represents a contractual milestone under the parties’ 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using Dyadic’s proprietary microbial expression platforms. With achievement of this milestone, Dyadic has earned and received a $200,000 milestone payment and remains eligible to receive royalties on future commercial sales. Chymosin is the primary milk-clotting enzyme used in cheese manufacturing. The global market for dairy processing enzymes is estimated to be approximately $1.5–$2.0 billion annually, driven by increasing global cheese consumption and rising demand for sustainable, fermentation-derived alternatives to traditional animal-sourced enzymes. “This milestone reflects the strength of our partnership with Dyadic and our shared commitment to delivering innovative, sustainable enzyme solutions to the dairy industry,” said Michael Fooken Jensen, CEO of Inzymes ApS. “With final development activities successfully completed, we are advancing with preparations for commercialization in 2026. By combining Dyadic’s high-productivity microbial platforms with our scale-up and commercialization expertise, we are positioning this non-animal chymosin to meet evolving customer requirements for performance, consistency, and supply reliability.” Joe Hazelton, President and COO of Dyadic Applied BioSolutions, stated: “The achievement of this development milestone marks important progress under our agreement with Inzymes and demonstrates our ability to advance programs from development through commercialization. We believe our microbial expression platforms support efficient development and scalable manufacturing, and we look forward to expanding into additional enzyme and protein opportunities across our business segments.” Additional non-animal dairy enzyme candidates continue to progress under the collaboration, supporting expansion of the companies’ portfolio within the growing market for fermentation-derived food enzymes. The successful completion of final development steps toward commercialization further reinforces the versatility of Dyadic’s platforms across food and nutrition, life sciences, and industrial biotechnology applications. About Dyadic Applied BioSolutions Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit . About Inzymes ApS Inzymes ApS is a Denmark-based enzyme innovation company focused on the development, scale-up, and commercialization of high-performance enzymes for food and beverage applications. Leveraging expertise in fermentation, formulation, and industrial enzyme deployment, Inzymes partners across the value chain to deliver sustainable, food-grade enzyme solutions that improve functionality, efficiency, and product quality. The company is committed to advancing next-generation bioprocessing technologies that support a more sustainable global food system. For more information please visit.
Biotechnology company Zura Bio recently announced the official completion of its public offering totaling $144 million.
In this issuance, the underwriters fully exercised the over-allotment option, demonstrating strong market confidence in the company's development prospects. The injection of these funds will provide important support for Zura Bio to advance its innovative therapy research and development.
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic manufacturing partnership with Syrma Johari MedTech Ltd. ("Syrma Johari"). The shipment marks a significant step in scaling the Company’s production capacity and validates the operational and financial benefits of the collaboration announced in December 2025. The readers are now being deployed across key customer verticals, including construction, transportation and logistics, and manufacturing, throughout the U.K. and Europe, supporting growing commercial demand and expanding the Company's installed base ahead of planned entry into the U.S. market, beyond the Forensic Use Only category, later this year. The successful first reader shipment confirms that the Syrma Johari partnership is performing as planned, with readers meeting INBS' quality standards and manufactured in compliance with ISO 13485, MDSAP, and applicable regulatory requirements. With access to manufacturing capacity approximately four times its prior capability, the Company is now positioned to accelerate fulfillment and is on track to deliver annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross margin annually. In addition to scaled reader production, INBS has considerably enhanced its manufacturing capabilities for the lateral flow test strip integral to its testing system. The Company has sourced advanced lateral flow manufacturing equipment that has doubled its in-house production capacity, delivering multiple strategic advantages including greater control over critical components that improve margins and reduce lead times, increased cartridge output that provides the product development team with expanded testing inventory for faster innovation cycles, and the ability to produce cartridges with additional test lines that unlock opportunities to explore expanded drug panels tailored to specific customer segments, regulatory markets, or emerging substance trends. "Receiving and deploying our first shipment of readers from Syrma Johari, combined with doubling our in-house lateral flow test strip production capacity, is a transformational step in our ability to scale intelligently and profitably," said Callistus Sequeira, Vice President of Global Quality & Operations at Intelligent Bio Solutions. "We are building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion, accelerates innovation, and positions us to enter the U.S. market with operational strength and the capacity to grow with demand." The Company expects additional production shipments throughout 2026 as it continues to build inventory, expand its commercial footprint, and execute on its U.S. regulatory and go-to-market strategy. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. Forward-Looking Statements
BIO-key and RunLevel Strengthen Identity Security Across Mozambique's National Payments Infrastructure for Sociedade Interbancaria de Mocambique (SIMO)
Multi-year agreement supports secure digital transformation of banking services and interbank systems MAPUTO, Mozambique and HOLMDEL, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global leader in biometric-centric Identity and Access Management (IAM) solutions, today announced a new strategic, multi-year agreement with Sociedade Interbancária de Moçambique (SIMO), the operator of Mozambique’s national electronic payments network. Working in partnership with RunLevel, a specialized regional integrator with identity and cybersecurity experience across Africa, BIO-key will support the modernization of identity and access security across SIMO’s financial ecosystem. The agreement builds on BIO-key’s and RunLevel’s first joint IAM deployment in Mozambique, in May 2025, for a major National Bank. Under initiative, BIO-key’s PortalGuard® IAM platform, PIN:You™ tokenless authentication, and Single Sign-On (SSO) capabilities will be integrated into SIMO’s environment to improve governance, boost cybersecurity resilience, and streamline secure access for institutions participating in the national payments infrastructure. The agreement supports SIMO’s long-term strategy to adopt enterprise-grade identity security aligned with international best practices while continuing to modernize Mozambique’s financial sector. The deployment represents BIO-key’s 11 th banking and financial sector customer globally. SIMO plays a key role in Mozambique’s banking system, by enabling interoperability, clearing, and settlement services across banks and financial service providers via the country’s single national electric payments network known as SIMOrede. As digital banking adoption accelerates to serve Mozambique population of 36.6 million, the need for strong, identity-first security has become critical to maintaining trust, operational continuity, and regulatory compliance. “As Mozambique’s financial system continues to evolve, identity security is vital for ensuring trust, interoperability, and operational resilience across payment services,” said Juna Chiloveque, SIMO’s IT Security and Compliance, CISO. "Partnering with BIO-key and RunLevel allows SIMO to adopt modern identity and access management solutions that strengthen governance, protect essential systems, and support the secure digital transformation of our national payments infrastructure.” “Partnering with SIMO and BIO-key on this project demonstrates RunLevel’s commitment to strengthening digital trust across Africa’s financial ecosystems,” said Miguel Guerreiro, Managing Partner, RunLevel. “By combining local expertise with advanced IAM technologies, we are helping establish secure authentication foundations that allow banks to innovate confidently while safeguarding critical payment infrastructure.” “Our collaboration with SIMO marks an important step in supporting secure digital banking infrastructure in Mozambique,” said Alex Rocha, BIO-key’s Managing Director – International. “Together with RunLevel, we are deploying scalable IAM technologies that help financial institutions modernize access, reduce identity risks, and enable trusted digital services across the ecosystem.” About Sociedade Interbancária de Moçambique (SIMO) SIMO manages the country’s unified electronic payments system, enabling secure clearing, settlement, and interoperability across Mozambique’s banking and financial services network. SIMO plays an important role in advancing financial inclusion and digital transformation nationwide. About Runlevel Runlevel is a specialized cybersecurity solutions provider focusing on Portuguese-speaking African countries (PALOP) and Timor-Leste. The company delivers advanced IT security, infrastructure, and compliance solutions, helping organizations navigate the evolving cybersecurity landscape with best-in-class technology and expert consulting services. About BIO-key International, Inc. BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
What To Expect From Agilent's (A) Q4 Earnings
Life sciences tools company Agilent Technologies (NYSE:A) will be reporting earnings this Wednesday afternoon. Here’s what you need to know. Agilent beat analysts’ revenue expectations last quarter, reporting revenues of $1.86 billion, up 9.4% year on year. It was a satisfactory quarter for the company, with a narrow beat of analysts’ revenue estimates. This quarter, the market is expecting Agilent’s revenue to grow 7.4% year on year, improving from the 1.4% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Agilent rarely misses Wall Street’s revenue estimates. Looking at Agilent’s peers in the research tools & consumables segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Bio-Techne posted flat year-on-year revenue, beating analysts’ expectations by 2%, and Revvity reported revenues up 5.8%, topping estimates by 1.1%. Bio-Techne traded up 1.9% following the results while Revvity was down 7%. The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. Agilent is down 8.4% during the same time and is heading into earnings with an average analyst price target of $169.67 (compared to the current share price of $124.20). Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial Results further validate key FG-3246 Phase 2 monotherapy design elements, most importantly the inclusion of patients who have progressed on only one prior ARPI and integration of baseline FG-3180 PET for all enrolled patients FG-3246 Phase 2 monotherapy trial on track for interim analysis in 2H 2026 SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) from the investigator-sponsored Phase 1b/2 study will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026 in San Francisco, CA. “The results from this Phase 1b/2 investigator-initiated study demonstrate encouraging preliminary anti-tumor activity of FG-3246 in combination with enzalutamide in patients with mCRPC. Notably, the 10.1 months of rPFS in patients with only one prior ARPI underscores the potential of FG-3246 in earlier lines of therapy,” commented Dr. Rahul Aggarwal, Professor of Medicine at the University of California San Francisco, and Principal Investigator of the study. “The positive trend observed in the association between tumor uptake of FG-3180 (CD46-targeting PET) and PSA50 response, though from a small number of patients, is especially intriguing and I’m excited to see the potential utility of this biomarker further explored in the Phase 2 monotherapy study.” “These data from the investigator sponsored trial expand on the clinically meaningful results previously observed with FG-3246,” said Thane Wettig, Chief Executive Officer of Kyntra Bio. “The 10.1 months of median rPFS observed in patients progressing on only one prior ARPI, and the mitigation of neutropenia related adverse events with prophylactic G-CSF are especially encouraging as they further validate our Phase 2 monotherapy trial design. We look forward to sharing the interim analysis of the Phase 2 monotherapy trial in the second half of 2026 as well as further characterizing the potential utility of FG-3180 as a patient selection biomarker.” The presentation includes data from 44 biomarker unselected patients with progressive metastatic castration-resistant prostate cancer, 17 of which were enrolled in the Phase 1b dose escalation portion of the study. Eligibility criteria for the trial included patients who progressed on at least one prior ARPI while patients who were treated with prior chemotherapy in the castration-resistant setting were excluded. Over 60% of the patients progressed on two or more prior ARPIs, which included prior enzalutamide treatment. The primary endpoint of the escalation phase was assessment of dose-limiting toxicities (DLT) and determination of the maximum tolerated dose and recommended dose for the Phase 2 portion of the study – which was determined to be 2.1 mg/kg of FG-3246 and 160 mg/day of enzalutamide. The primary endpoint of the Phase 2 expansion portion of the study was composite response rate (PSA50 response and/or objective response per RECIST v1.1). Secondary endpoints were PSA50 response rate, objective response rate, radiographic progression free survival (rPFS), overall survival, and treatment-related adverse events (TRAEs). FG-3246 combined with enzalutamide demonstrated anti-tumor activity with a composite response rate of 21% in the overall cohort and 40% in patients who had progressed on only one prior ARPI. Median rPFS of 7.0 months was observed in the overall cohort. Notably, median rPFS of 10.1 months was observed in patients who had progressed on only one prior ARPI, a result which was consistent across the different prior ARPIs administered. Additionally, higher tumor uptake of FG-3180 demonstrated a trend towards higher probability of PSA50 response (p=0.053), highlighting the potential of FG-3180 as a biomarker for patient selection. Combination therapy of FG-3246 and enzalutamide demonstrated a similar safety profile as was observed in the previous Phase 1 monotherapy trial of FG-3246. Neutropenia risk was successfully mitigated with use of G-CSF prophylaxis. The most frequent TRAEs with the combination therapy included fatigue, peripheral neuropathy, anorexia, and dysgeusia. Cumulative toxicities, including peripheral neuropathy, led to treatment discontinuation for some patients. The poster presentation, titled “A phase 1b/2 study of FOR46 (FG-3246) in combination with enzalutamide (enza) in patients with metastatic castration resistant prostate cancer (mCRPC)”, is scheduled for the poster session taking place on February 26, 2026 from 11:30 AM to 12:45 PM PT. FG-3246 is currently being evaluated in a Phase 2 monotherapy trial with interim data expected in the second half of 2026. The trial also includes treatment with FG-3180, a CD46-directed PET imaging agent, which will measure expression levels of CD46 positive lesions. This will enable further assessment of the correlation between CD46 expression and response to FG-3246 and the potential of FG-3180 to serve as a biomarker to aid in patient selection in future trials of FG-3246. About FG-3246 and FG-3180 FG-3246 (FOR46) is a potential first-in-class fully human antibody-drug conjugate (ADC), exclusively in-licensed from Fortis Therapeutics, and is being developed by Kyntra Bio for metastatic castration-resistant prostate cancer and potentially other tumor types. FG-3246 binds to an epitope of CD46, a cell receptor target, that induces internalization upon antibody binding, is present at high levels in prostate cancer and other tumor types and demonstrates very limited expression in most normal tissues. FG-3246 is comprised of an anti-CD46 antibody, YS5, linked to the anti-mitotic agent, MMAE, which is a clinically and commercially validated ADC payload. FG-3246 has demonstrated anti-tumor activity in both preclinical and clinical studies. FG-3180 is a companion diagnostic PET imaging agent, using the same CD46-targeting antibody together with an 89 Zr tracker. To date, FG-3180 demonstrated specific uptake in CD46 positive tumors and is currently being evaluated as a biomarker for its potential to inform patient selection. About the Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide This Phase 1b/2 study is an investigator-sponsored trial being conducted at the University of California San Francisco to evaluate FG-3246 (FOR46) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) after prior progression on at least one androgen receptor pathway inhibitor. The primary objective for the Phase 1b portion of the study is to determine the maximally tolerated dose (MTD) and recommended Phase 2 dose of FG-3246 in combination with enzalutamide in patients with mCRPC. The objectives of the Phase 2 portion of the study are to determine the composite response rate (CRR), proportion of participants with a greater than or equal to 50% change in prostate specific antigen (PSA50), objective response rate (ORR), median duration of response, median radiographic progression free survival (rPFS), and median overall survival (OS) of patients treated with FG-3246 in combination with enzalutamide. About Kyntra Bio Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓 ® , EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker.
Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026
CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its participation in World Health Expo Dubai 2026 (formerly Arab Health), one of the world’s largest and most influential healthcare exhibitions and conferences. The Expo was held February 9–12, 2026, at the Dubai Exhibition Centre in Expo City Dubai, United Arab Emirates, where Cosmos Health exhibited at Booth SA.A79. The event, which accommodates more than 235,000 visitors and over 4,300 exhibitors from more than 180 countries, brings together healthcare leaders, distributors, manufacturers, and innovators to explore emerging trends, foster strategic partnerships, and advance international collaboration within the healthcare sector. At the exhibition, Cosmos Health showcased its growing portfolio of proprietary nutraceutical and wellness brands, led by its flagship Sky Premium Life® line of nutraceuticals, which continues to gain global traction through expanded distribution agreements, new product introductions, and increasing international demand. The brand’s premium formulations have strengthened its presence across the key markets in Europe and the Middle East, while its recent expansion into the North American market through the NOOR line is supported by Cosmos Health’s U.S.-based manufacturing capabilities. The Company also highlighted several of its other healthcare and consumer brands, including C-Scrub®, its antiseptic wash formulated to deliver reliable antimicrobial properties and support effective hand and skin hygiene, as well as Mediterranation®, its proprietary luxury nutritional supplement line featuring formulations that incorporate organic herbs and plant extracts traditionally sourced from Greece and the broader Mediterranean region, including crataegus, hibiscus, dittany of Crete, oregano, mastic, and kritamos. The Company’s presence at the Expo provided an opportunity to raise awareness of its vertically integrated manufacturing capabilities and to engage with potential commercial partners, distributors, and industry stakeholders. Greg Siokas, CEO of Cosmos Health, stated: “Participating in World Health Expo Dubai underscores our commitment to expanding the global footprint of our proprietary brands. Sky Premium Life continues to gain international momentum, and this platform enables us to strengthen strategic relationships, expand distribution opportunities, and showcase the depth and quality of our portfolio. During the exhibition, we held highly productive meetings with participating parties from new regions and territories, ranging from Japan and China to several Latin American countries, and we are currently in the process of advancing several potential agreements. We remain focused on disciplined growth, brand development, and long-term value creation.” About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time. As such, the Zacks rating upgrade for Boundless Bio, Inc. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Boundless Bio, Inc. imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher. Harnessing the Power of Earnings Estimate Revisions Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> . Earnings Estimate Revisions for Boundless Bio, Inc. For the fiscal year ending December 2025, this company is expected to earn -$2.45 per share, which is unchanged compared with the year-ago reported number. Analysts have been steadily raising their estimates for Boundless Bio, Inc.. Over the past three months, the Zacks Consensus Estimate for the company has increased 34.5%. Bottom Line Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Boundless Bio, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Bio-Rad: Fourth Quarter Financial Highlights
Bio-Rad Laboratories Reports Strong Fourth Quarter Results Bio-Rad Laboratories Inc., headquartered in Hercules, California, announced a net profit of $720 million for the fourth quarter, marking a turnaround from a loss during the same period last year. The company reported earnings of $26.65 per share for the quarter. When excluding one-time gains, adjusted earnings stood at $2.51 per share. During this period, Bio-Rad, a provider of scientific instruments for biomedical research, generated $693.2 million in revenue. For the full year, Bio-Rad achieved a net income of $759.9 million, or $27.85 per share, moving into profitability. Annual revenue reached $2.58 billion. Since the start of the year, Bio-Rad's stock price has decreased by 3.5%. At the close of trading on Thursday, shares were valued at $292.42, reflecting a decline of just over 6% over the past year.
Analysis-Global shipping industry sticks with green investments, despite carbon price delay
By Enes Tunagur and Jeslyn Lerh LONDON/SINGAPORE, Feb 12 (Reuters) - The shipping industry's biggest players are shrugging off Trump administration opposition to a global carbon price and are forging ahead with billions of dollars in emissions-reducing investments, according to company officials and a Reuters analysis of data. Europe, Brazil and a host of other nations are pushing the sector, which is responsible for nearly 3% of the world's greenhouse gas emissions, to go green. But, in October, the U.S. and Saudi Arabia, the world's two largest oil producers, successfully spearheaded efforts to postpone by one year a decision on the International Maritime Organization's proposal of a $380-per-metric-ton levy. Some analysts and industry observers initially warned that the absence of such a global framework added complexity to companies' planning and could cause some to pause their green investments. But in interviews with 15 shipping companies, ports, bunker suppliers and marine technology companies, 10 told Reuters that regional regulations, long investment lead times, and expectations of a continuing trend towards decarbonisation all argued in favour of staying the course. And a Reuters analysis of vessel delivery data through 2028 showed orders of ships capable of running on alternative fuels dominating new shipbuilding. Hakan Agnevall - chief executive of Wartsila, a major producer of ship engines and exhaust gas cleaning scrubbers - told Reuters that a one-year carbon price postponement is unlikely to rattle customers, like his, who generally take a 30-year investment perspective. "It's not bold to say that regulations will change during those 30 years." DUAL-FUEL VESSELS DOMINATE NEW SHIP ORDERS Most of the nearly 50,000 commercial ships operating globally today run on fuel oil or gas oil. But in a unanimous decision in 2023, IMO member states set a target of net-zero emissions by or around 2050. Firms have, in anticipation, begun ordering dual-fuel ships that can use both fuel oil as well as greener alternatives like liquefied natural gas, methanol and ammonia. While Pacific Basin - a large dry bulk ship owner - did opt to buy four newbuild vessels running only on oil-derived fuels, citing the postponement of the IMO's carbon price, the company is an outlier. Unlike other sectors - from energy to auto manufacturing - that have curbed their green ambitions in a rollback that has only accelerated since Donald Trump's return to the White House, the shipping industry has, so far, declined to pivot. Major ship owners have reiterated their commitments to invest in emissions reduction measures, including dual-fuel vessels and onboard energy-saving devices. By the end of December, companies had invested over $150 billion in dual-fuel vessels, according to a Reuters analysis of data from the World Shipping Council, an industry group for container shipping and vehicle carriers. In total, 1,126 dual-fuel container ships and vehicle carriers have now been either delivered or are on order, the data showed. That marks an increase of 28% compared with the previous year, indicating that newbuilding orders for lower-emission fuel vessels continued even after the IMO delay. They also continued to outpace orders for traditional ships, with dual-fuel vessels now accounting for 74% of the overall container ship and vehicle carrier orderbook. And investments in new marine fuels are also moving ahead. Alexander Saverys, CEO of Belgian ship owner CMB.Tech, told Reuters it will continue investments in both ammonia bunkering and production. A Mitsui O.S.K. Lines spokesperson told Reuters the IMO postponement just means a longer transition to low and zero-carbon fuels, and the company is still focused on LNG-fuelled vessels and early-stage adoption of ammonia and methanol. Maersk, among the first to explore emissions-reducing alternative fuels, initially opted for methanol but has since ordered LNG-fuelled ships and has now also started testing ethanol as an alternative. NYK Group, which reaffirmed its emissions reduction strategy after the IMO decision, sees the one-year delay as an opportunity for discussion and refinement of the regulatory framework, a company spokesperson said. "While recent regulatory uncertainties might lead some operators to take a more cautious approach, the overall direction of maritime decarbonisation has not changed significantly," said Jason Stefanatos, decarbonisation director at maritime consultancy DNV. "The commercial drivers still remain." DESPITE IMO DELAY, GREEN INCENTIVES ARE EXPANDING GLOBALLY Many companies cited regional green fuel regulations among the main reasons for moving ahead with investments. The European Union's FuelEU Maritime, which requires vessels to pay penalties for failing to achieve lower emissions, makes a business case for greener fleets, ship owners and fuel suppliers said. And the EU Emissions Trading System and voluntary initiatives provide further incentives. Ship owners with dual-fuel vessels will likely use them on EU voyages to avoid paying FuelEU Maritime penalties, and some should also receive rewards for over-compliance, said Kenneth Tveter, an analyst at shipbroker Clarksons. "The case for low-carbon fuels such as ammonia and methanol is still alive if you have a trade concentrated around Europe," he said. Major Horn of Africa port Djibouti and OPEC member Gabon have also introduced levies on maritime emissions. And current momentum could see punitive regulations and incentive schemes introduced in other important shipping hubs soon. Britain, notably, has proposed to expand its emissions trading system to international shipping from 2028. And Turkey is considering a scheme similar to the EU's. Such factors should drive demand for LNG, bio-LNG and biofuels over the next five years, said Nacho de Miguel, head of alternative fuels at bunker supplier Peninsula. "Whilst the IMO's net-zero framework has been postponed, this does not change our strategy," he said. (Reporting by Enes Tunagur in London and Jeslyn Lerh in Singapore; Additional reporting by Georgina McCartney; Editing by Alex Lawler and Joe Bavier) View comments
On the premier platform for biotechnology, revived enthusiasm faces a critical examination
Biotech Industry Sees Renewed Optimism Amid Lingering Uncertainty At this year's J.P. Morgan Healthcare Conference in San Francisco, Alexis Borisy—a well-known biotech investor and co-founder of Curie.Bio and Revolution Medicines—found himself conducting meetings from a hotel suite, seated on a powder blue couch reminiscent of a giant pill. With a hearty laugh, he acknowledged the fitting symbolism. Borisy, who has attended the conference since its early days under Hambrecht & Quist, noted a marked shift in sentiment this year. For the first time in several years, attendees seemed genuinely hopeful about the sector's prospects—and with good reason. After a prolonged slump that began in late 2021, the biotech industry is finally showing signs of recovery. The latter half of last year saw a surge in acquisitions, with at least 28 deals valued at $50 million or more announced. Investment is also rebounding. According to HSBC’s Innovation Banking, 157 venture capital transactions totaling $7 billion took place in the fourth quarter alone. RBC Capital Markets reported $22 billion in biotech investments during the last three months of 2025, matching the heights of the 2020-2021 boom. The positive momentum has carried into 2026, with Raymond James analysts highlighting $1.2 billion in biotech inflows during the first week of the year. “We’re in a strong position as a sector right now,” remarked John Maraganore, founding CEO of Alnylam Pharmaceuticals and former chair of the industry’s largest trade association. However, beneath the optimism lies a sense of caution. Many worry that the recovery could be short-lived if the industry fails to navigate upcoming challenges wisely. This tension was palpable throughout the conference. The absence of major deals on the opening day frustrated many, with investor-turned-analyst Brad Loncar calling it “the slowest JPM for news in a long time.” The XBI biotech fund ended the event with little change. Borisy likened the current phase to the early stages of a recovery, cautioning, “We can’t be certain yet. When you’re at the bottom, false starts are possible, and it can take time to truly rebound.” Shifting Dynamics in Global Biotech Industry experts agree that the sector is being shaped by a complex interplay of forces. The rapid advancement of China’s biotech industry, for instance, has sparked concerns about the U.S. losing its leadership in life sciences. Yet, some believe this competition could drive American drug developers to become more agile and innovative. The U.S. Food and Drug Administration (FDA) has just emerged from one of its most turbulent years, but the agency has also demonstrated a willingness to expedite drug approvals. Pharmaceutical companies have adapted well, showing skill in negotiating with the Trump Administration on broader policy matters. Still, uncertainty remains. Recent leadership changes at the FDA have left many investors uneasy. A recent RBC survey found that more than half of biotech investors view regulatory unpredictability as the sector’s biggest challenge. “We’re all hoping for greater stability and consistency from the FDA,” Maraganore said. “Delays or inconsistencies would be concerning, but I remain hopeful.” Public Markets and Funding Trends Public investors, who had largely overlooked drug startups in recent years, now appear ready to support these companies again. This renewed interest could influence dealmaking, potentially allowing smaller biotechs to rely less on partnerships with large pharmaceutical firms or to advance their research further before seeking collaborators. “If the IPO market opens up more in 2026, it doesn’t mean partnerships will disappear,” said Adam Keeney, head of corporate development at Biogen. “It just means companies might reach more advanced stages before partnering, which benefits everyone.” Keeney added, “We’re not at bubble territory yet.” Lessons from the Last Boom If the recovery endures, industry stakeholders will need to avoid the pitfalls of the previous hype cycle, when unproven drug startups rushed to go public with little clarity on their business models. Many of those companies struggled when the market corrected, disappointing investors and prompting many generalist backers to exit the sector. Developers of cell and gene therapies, as well as “platform” companies promising a pipeline of new medicines, were especially hard hit. “You can’t get swept up in the excitement,” cautioned Andy Plump, head of R&D at Takeda Pharmaceutical. He noted that while platform companies were once highly sought after, “the reality is platforms often fail. The hype just isn’t worth it.” Recent trends in public markets reflect a more cautious approach. Last year, all but one biotech IPO involved companies with drugs already in Phase 2 trials or later, and most are now trading above their initial offering prices. One such company, Metsera, was recently acquired in a $10 billion deal. Some interpret this as evidence that emerging drug companies and their investors have become more disciplined and efficient. Maraganore described the recent downturn as a “Darwinian survival of the fittest,” resulting in a stronger crop of private companies. “The private companies that remain are exceptionally strong,” he said. “I believe the next wave of IPOs could feature some of the best companies we’ve seen in years.” Risks of Overheating Given the cyclical nature of biotech, a sustained upswing could eventually lead to another bubble. Momentum investors, drawn by promising clinical results or rising stock prices, may drive valuations even higher. Borisy warned that this could result in overcapitalization and a subsequent downturn. Some analysts are already raising red flags. RBC’s December report cautioned that the XBI’s strong performance in 2025 had left many companies with valuations reflecting “excessive optimism.” They warned that future growth could be harder to achieve, and any disappointing results might trigger sharp declines in share prices. Keeney of Biogen emphasized the need for collective discipline: “If we stay focused, more capital can be directed toward the companies with the greatest potential for success.” Early-stage investors seem to be following this advice. Large fundraising rounds of $100 million or more have become common, as bigger, slower-moving investors concentrate their resources on fewer companies that remain private longer, viewing these investments as safer bets. While many venture capitalists claim to have learned from past cycles, skepticism remains. Borisy, for his part, expressed some doubt about whether the industry has truly changed. “You can note that I rolled my eyes,” he quipped.
Bio Protocol token BIO launches on BNB Chain
Foresight News reported that the decentralized science (DeSci) platform Bio Protocol has announced that its token BIO is now tradable on BNB Chain. In addition, Bio Protocol stated that more DeSci tokens will be launched on BNB Chain to support Bio's Launchpad and the development of x402's BioAgents on BNB Chain.
Decoding VitaDAO: A Paradigm Revolution in Decentralized Science
🌱 VitaDAO: A New Experimental Ground at the Intersection of Biotechnology and Blockchain How can decentralized organizations change drug development? How can longevity research become more transparent and efficient? Dive in and unlock VitaDAO's scientific revolution together! 🚀 #DeSci #VitaDAO Project Overview VitaDAO is a DAO collective for community management and decentralized drug development. Its core mission is to accelerate R&D in the longevity field and extend human lifespan and healthspan. To achieve this, VitaDAO collectively funds and digitizes research in the form of IP-NFTs and spins off new biotech companies. Problems to solve: Medical and biological research funding applications to NIH are highly bureaucratic and slow. There is a gap between novel ideas and commercialization, and the project aims to fill this early-stage gap. $VITA Data Layer Contract Address: 0x81f8f0bb1cb2a06649e51913a151f0e7ef6fa321; Token Price: Currently reported at $4.04 Token Market Cap: $111 millions Number of Holder Addresses: 2790+ According to Coingecko data, $VITA's all-time high reached $6.34, with a 24-hour fluctuation range of $3.76-5.02. The price shows strong resilience. Since Vitalik showcased VitaDAO's first product VD 001 to CZ in Bangkok, VITA has entered a surge mode, with an intraday peak increase of 82.4%. The latest price is $4.04, market cap exceeds $111 millions, and the price has nearly tripled in the past week. It is worth noting that security issues can be seen on GMGN, as the project team has neither locked the pool nor renounced ownership, posing certain risks. However, smart money and whales still show a favorable attitude towards it. The VitaDAO treasury currently holds assets worth about $55.84 millions, including $14.3 millions in VITA, $1.14 millions in WETH, and a series of IP assets and IP-NFTs valued at $38 millions. In addition, VitaDAO will receive 21 million BIO tokens through the Bio Protocol's bio/acc reward program. BIO Protocol has completed its initial token offering, and founder Paul Kohlhaas stated that BIO's Launchpad and token transferability features will be launched in the first quarter of next year. VitaDAO has also launched the VITA-FAST token in collaboration with Newcastle University's Viktor Korolchuk Lab. The Viktor Korolchuk Lab team is dedicated to identifying compounds that may initiate autophagy and rejuvenate senescent cells. The VITA-FAST token sale ended last year with a 1700% oversubscription, and the price has increased sixfold in the past week, with a market cap of $23 millions. VITA-FAST was created by a vote of VITA token holders and is officially described as the first longevity IPT implemented on Molecule through the tokenization of Korolchuk IP-NFT. Market Trading Pairs Uniswap VITA/WETH XT.COM VITA/USDT Uniswap VITA-FAST/VITA Ourbit VITA/USDT CoinEx VITA/USDT Uniswap VITARNA/VITA BingX VITA/USDT Balancer VITA/WETH Funded Projects Matrix Bio: Researches the anti-cancer and longevity effects of high molecular weight hyaluronic acid from naked mole rats on humans, initiated in March 2023. In October of the same year, VitaDAO launched the biotech company Matrix Bio, provided $300,000 in funding, and will raise funds through IP-NFT fractionalization; Scheibye-Knudsen Lab: Uses machine learning to process 1.04 billion prescription data to understand the impact of drugs on human lifespan; Fang Lab: Combines AI technology and a wet lab validation platform to identify new mitophagy-activating candidate drugs for Alzheimer's disease. Established the Fang-AI lab validation platform and successfully screened two lead compounds as drug candidates for AD. The project plans to use WP1 to screen new apoptosis activators from the compound library of the Finnish Institute for Molecular Medicine (FIMM) using Fang-AI and the lab validation platform, and use WP2 for AI structural modification and lab validation of two natural compounds, EFF-AA and EFF-BA. The total cost of the project is expected to be between $2.5-4 millions, and the DAO will own 100% of the project and related intellectual property. An Lab: Focuses on reversing periodontitis. The research results are expected to provide important preclinical IP data for non-surgical treatment methods for periodontal diseases and may drive the establishment of new companies. Humanity: This project connects wearable devices to monitor digital biomarkers, quantifies aging scores, and provides scientific evidence for personalized aging management; GERO: Uses physics and AI to understand the aging process and creates pipelines for candidate drugs and therapies targeting multiple age-related chronic diseases to slow aging; Oisín Biotechnologies: Develops gene medicines to combat sarcopenia and other age-related diseases. The product line includes therapies to stimulate muscle growth, selectively destroy fat cells, and eliminate senescent cells. Oisín Biotechnologies also completed a $15 millions Series A financing in July 2024, led by AbbVie Ventures, the investment arm of US pharmaceutical giant AbbVie. The funds will mainly be used for research on eliminating unwanted fat cells and enhancing muscle mass. Mantis Photonics: A hyperspectral imaging device for early diagnosis of Alzheimer's disease. The project has already obtained two patent protections and is supported by a peer-reviewed proof-of-concept study. Michal Siewierski: Funded the longevity hacker film "Longevity Hackers" to promote scientific research in the healthspan field and raise public awareness and interest in the field. Repair Biotechnologies: A preclinical-stage biotech company developing a universal cell therapy for atherosclerosis, aiming to reduce cardiovascular event risk and improve the efficacy of existing drug treatments. HDAX Therapeutics: Develops HDAC6 inhibitors with higher blood-brain barrier penetration and lower toxicity. Has shown potential to extend lifespan in animal models. ExcepGen Inc: Develops an RNA therapy platform called RNAx, which improves RNA vaccine efficacy by optimizing RNA delivery and regulating cell signaling, especially for hard-to-target antigens such as universal influenza viruses. Cyclarity Therapeutics: Develops a new cyclodextrin capsule drug based on computational design, aiming to extract harmful biomolecules such as oxidized cholesterol accumulated in the body, especially in cardiovascular diseases. Recent Developments The funded VitaRNA/Artan Bio team recently successfully identified and validated two promising lead candidates from an initial screening of 15 candidate oligonucleotides and has reached a manufacturing partnership with biotech multinational Lonza to ensure that VitaRNA's main candidate drug ARTAN-102 will be produced according to industry standards for preclinical and clinical research. VitaRNA/Artan Bio previously raised $300,000 through IP-NFT tokenization and will have the next round of sales in Q1 2025. On October 17, VitaDAO launched the internal interdisciplinary scientist network VitaLabs, aiming to develop aging research internally and enhance the democratic ownership of intellectual property through Intellectual Property Tokens (IPT). Specifically, VitaLabs will form interdisciplinary teams during each 4-month window to discover ideas and conduct experiments, as well as regularly update data. Successful projects will advance to in-depth research and potential derivative creation. VitaDAO also launched the VitaLabs Fellowship Program to attract talent to participate in longevity research. Team and Funding _ Position Tyler Golato Molecule Founder & Chief Scientist Tyler Golato once worked at the US National Institute on Aging (NIH / NIA / IRP), studying under Dr. David M. Wilson III and Dr. Vilhelm Bohr, focusing on repairing endogenous DNA damage. He also worked at the Robert Fine Laboratory at Columbia University, researching the mechanisms of chemoresistance in pancreatic cancer and developing novel therapeutic strategies for various cancers. 2023-01-30: Investment amount $4.08 millions; investment round not disclosed Investors include: Shine Capital, L1D, Spaceship DAO, Beaker DAO, Balaji Srinivasan, Pfizer, Joe Betts-LaCroix 2021-06-23: Public round investment; investment amount $5.1 millions Investors not disclosed Summary The DeSci track is not a newly emerging field; as early as 2023, CZ mentioned it on Twitter. However, DeSci only briefly attracted attention, and subsequent development was lukewarm and did not receive much market attention until recently when Binance Labs announced its investment in BIO Protocol and CZ and Vitalik jointly participated in a DeSci conference, bringing the track back into the public eye. The main goal of DeSci is to leverage the decentralized, transparent, and tamper-proof characteristics of technology to solve a series of pain points in the traditional scientific research system, including uneven distribution of research funding, unclear ownership of intellectual property, high barriers to academic publishing, and inefficient interdisciplinary collaboration. Core applications in DeSci include: Decentralized funding: Supporting research projects through smart contracts and token mechanisms to reduce unfairness in funding allocation. Intellectual property protection: Using blockchain to record ownership of research results, ensuring that the attribution of each research achievement is transparent and immutable. Open scientific publishing: Eliminating the intermediary role of traditional journals and promoting the rapid sharing and dissemination of research results. Interdisciplinary collaboration: Building open collaboration platforms to enable efficient cooperation among researchers worldwide. VitaDAO is one of the benchmark projects in the DeSci track, focusing on anti-aging and longevity research, exploring how decentralized governance models can drive innovation in the life sciences field. VitaDAO was established as early as 2021 and even received investment from the world-renowned pharmaceutical company Pfizer. Its decentralized design not only empowers researchers and investors but also drives innovation and acceleration in biomedical technology. The successful implementation of DeSci solutions by VitaDAO has brought a fully decentralized funding and collaboration platform to global life sciences research. It provides a mature reference for the DeSci model: managing funding allocation and intellectual property through smart contracts to maximize transparency and efficiency in the research process. Building a more inclusive research ecosystem is an important goal of DeSci, and VitaDAO's community-driven mechanism is a model of this goal. Its decentralized governance model not only makes research decision-making more democratic but also lowers the resource requirements for research participants, which is especially significant for independent scientists lacking traditional funding channels. Promoting the rapid transformation of research results: In the traditional research system, the transformation of results from the laboratory to practical application is often lengthy and costly. VitaDAO's distributed collaboration and open intellectual property sharing model greatly shorten the transformation cycle of research results and facilitate the rapid commercialization of scientific achievements. With the continuous maturity of decentralized technology and blockchain, VitaDAO has the potential to become an important platform for future research funding and innovation. Of course, it still faces challenges in regulation, funding, and community collaboration. Whether it can overcome these bottlenecks in the future will determine its influence in the global biomedical field.
BIO Protocol: BioXP Season 2 Upgrade Introduces New Mechanisms and Ecosystem Airdrop
Foresight News reports that Bio Protocol has announced significant upgrades for BioXP Season 2, changing the way users earn rewards within the Bio ecosystem. The new BioXP system requires users to stake BIO to generate veBIO in order to earn experience points (XP) through staking ecosystem tokens. In addition, veBIO holders will automatically receive airdrops of new tokens when they are launched. The new mechanism includes three types of multipliers: BIO staking multiplier, level multiplier, and new token multiplier, with a maximum yield of up to 10 times. The first launch sale of Season 2 is about to take place, and BioXP with a duration of more than 14 days will immediately become invalid.
What Altcoins Whales Are Buying After the Early November Crypto Crash?
The early-November crypto crash caught the market off guard, contradicting expectations of a strong, bullish month. Between November 4 and 5, sharp pullbacks across major tokens disrupted sentiment and erased short-term gains. Even so, altcoins that whales are buying continue to stand out. On-chain data shows large holders quietly accumulating tokens that display breakout structures, early divergences, and stronger technical setups. All are signs that big money may already be positioning for the next leg of recovery with or without retail participation. Aster (ASTER) The first altcoin that whales are buying after the early-November crash is Aster (ASTER), a BNB Chain project focused on decentralized trading. In the past 24 hours, Aster whales have increased their holdings by 12.58%, now owning 43.62 million ASTER. This means whales added roughly 4.9 million tokens, worth about $5.46 million at the current price. Interestingly, exchange balances rose by 0.72%, showing that while whales are quietly accumulating, some retail or early investors are likely taking profits — a pattern often seen when whales are buying altcoins during early recovery phases. ASTER Whales: Nansen Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here. On the technical front, ASTER continues to trade inside a falling wedge. It is a pattern that usually signals a potential bullish reversal as price compresses. The token’s sharp drop on November 4 was followed by a clear bullish divergence on the Relative Strength Index (RSI). It is a momentum indicator that compares recent gains and losses to identify whether an asset is overbought or oversold. Between October 10 and November 3, ASTER’s price made a lower low while RSI formed a higher low, hinting that selling pressure is easing. Since then, the ASTER price has been moving up steadily. If this momentum continues, a breakout above $1.28, followed by $1.53 — approximately 36.8% higher from current levels — would confirm the move and open a potential path toward $2.21. That would mean a wedge breakout and turn the ASTER price structure completely bullish. ASTER Price Analysis: TradingView However, the key support remains at $0.93, and if that fails, Aster could revisit $0.81 or lower if broader market conditions weaken further. Bio Protocol (BIO) The next altcoin that whales are buying after the early-November crash is Bio Protocol (BIO), a decentralized science (DeSci) project built on Ethereum. Despite being down 44.2% in the past month, the token has traded flat over the past 24 hours — suggesting that the sharp sell-off might be stabilizing. In the last day, Bio Protocol whales have increased their holdings by 87.07%, now holding 1.89 million BIO. That means they’ve added about 880,000 tokens. Mega whales — the top 100 addresses — also expanded their holdings by 0.07%, now sitting at 2.98 billion BIO, adding another 2.09 million tokens. Together, whales and mega whales picked up nearly 2.97 million BIO, valued at close to $226,000 — showing quiet but clear accumulation at lower levels. BIO Protocol Whales: Nansen The technical setup supports this accumulation phase. The On-Balance Volume (OBV) indicator, which measures cumulative buying and selling by adding volume on up days and subtracting it on down days, has been forming a downward trendline since late September. Between September 21 and October 27, OBV formed a series of lower highs, creating a clear resistance slope. On November 2, BIO’s OBV briefly broke above that line, leading to a price uptick between October 31 and November 2. Although the move failed initially, a new breakout attempt has begun, marked by a green daily candle. BIO Price Analysis: TradingView If this OBV breakout sustains, the first resistance to watch lies near $0.097, which aligns with the 50% Fibonacci retracement. A close above that could open the path toward $0.12 and $0.16, confirming bullishness. However, if BIO loses $0.066, it would fall back under its OBV trendline — signaling renewed weakness. That could make the bears’ eye new BIO price lows. Syrup (SYRUP) The third altcoin that whales are buying is Syrup (SYRUP). It is a DeFi token that powers Maple Finance’s staking and lending platform. Whale accumulation in Syrup has accelerated notably since November 4, immediately following the market-wide pullback. Two whale cohorts have been leading this move. The larger group, holding between 100 million and 1 billion SYRUP, has increased its balance from 447.95 million to 448.18 million SYRUP. That meant adding around 230,000 tokens in just two days. Meanwhile, smaller whale addresses holding 10 million to 100 million SYRUP have made a much stronger push. They raised their collective holdings from 397.29 million to 425.09 million SYRUP — an increase of about 27.8 million tokens. SYRUP Whales: Nansen Together, both cohorts have added nearly 28 million SYRUP (worth $11.50 million), reflecting clear confidence returning among large holders. This aggressive accumulation aligns with key technical signals. Between August 25 and November 4, the RSI (Relative Strength Index) on the daily chart formed a bullish divergence. The price made lower lows while RSI formed higher lows, often an early sign of trend reversal. Adding to that, the Chaikin Money Flow (CMF), which tracks whether capital is flowing into or out of an asset, has just broken marginally above its downward trendline drawn from October 14. This suggests fresh inflows from large wallets, further validating the whale-led accumulation. SYRUP Price Analysis: TradingView The next confirmation for SYRUP’s recovery would be if the CMF moves above zero, which would validate sustained buying momentum. On the price front, the first major resistance lies near $0.46, about 13% above current levels of $0.41. A close above it could push SYRUP toward $0.53 and beyond. On the downside, strong support sits at $0.36, and if that fails, the token could retest $0.31 or lower. Read the article at BeInCrypto
SecuX Wallet Adds USDC Support to XDC Network at Exclusive Hardware Discount
SecuX’s hardware wallet provider has announced that USDC stablecoin support is now available on the XDC Network. This marks a significant expansion in the partnership between the two blockchain infrastructure companies. The integration allows SecuX wallet users to store, direct, and receive USDC on XDC Network with rapid, low-cost transactions while maintaining cold storage security. SecuX is offering 20% off all hardware wallets using the code XDC20, which is valid through October 10, 2025. Strategic Alignment to the XDC Network Launch by Circle The timing of this integration is perfectly aligned with Circle’s recent launch of native USDC on the XDC Network. USDC was active on XDC in mid-September 2025, alongside Circle’s Cross-Chain Transfer Protocol V2, enabling developers and enterprises to access fully reserved stablecoin functionality without relying on wrapped tokens or third-party connections. As of August 2025, more than $67B in USDC has been distributed across multiple chains. This native approach provides users with enhanced security and direct 1:1 redemption for US dollars, unlike bridged versions that depend on custodians or third-party infrastructure. For SecuX users, this means access to battle-tested stablecoin infrastructure supporting billions in daily transactions across DeFi applications, real-world asset tokenization, and trade finance operations precisely the areas where XDC Network has built its reputation. Cold Storage Security Meets Enterprise Blockchain Efficiency SecuX’s hardware wallet line, which includes the V20, W20, W10, Nifty, Shield BIO, and Neo series models, provides vault-grade security through offline private key storage. The integration of the USDC on XDC Network empowers the users to secure cold storage and leverage the speed and cost-effectiveness of XDC enterprise blockchain. XDC Network is a blockchain protocol that can be tokenized, compatible with EVMs, and built to serve the trade finance sector. This business emphasis, along with domestic utility, makes it an ideal option to integrate USDC, particularly with institutions pursuing an interest in having reliable and auditable stablecoins. The integrated screen on the hardware wallet enables users to verify transaction information prior to authorizing transfers, resolving the main security concerns in stablecoins management. This is particularly important when dealing with larger transaction volumes in enterprise contexts. Expanding Network of XDC Networks The SecuX integration signals the development of mainstream infrastructure support for XDC Network as a viable enterprise blockchain. Hardware wallet support is often viewed as a maturing indicator for blockchain ecosystems, indicating sufficient user demand and technical reliability. The launch of native USDC on XDC Network enables the stablecoin to be a universal settlement layer, utilizing traditional finance and decentralized ecosystems. As SecuX now offers secure custody options, the infrastructure is becoming more extensive to a more comprehensive institution. Users who have already acquired XDC tokens can manage USDC on the same secure hardware interface, which simplifies portfolio management and reduces security risks in comparison to having multiple wallet solutions. Conclusion SecuX has introduced the USDC to XDC Network to meet the evolving infrastructure of blockchain-based enterprise ecosystems. The integration supports the real-world requirements in the market by integrating hardware-level security and Circle, which provides a fully reserved stablecoin on a network designed to provide real-world business applications. The time-sensitive discount is an opportunity for users who feel like purchasing their XDC Network resources, while the broader integration is an indication of the enterprise blockchain infrastructure moving towards an institutional level.
Filled orders
Delivery scenarios